BHCM
FOLD

Brevan Howard Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Brevan Howard Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,235
Closed -$246K – 1964
2025
Q3 		$246K Sell
31,235
-66,453
-68% -$473K ﹤0.01% 1660
2025
Q2 		$560K Buy
+97,688
New +$630K ﹤0.01% 1310
2025
Q1 		– Sell
-18,266
Closed -$172K – 1260
2024
Q4 		$172K Sell
18,266
-26,094
-59% -$271K ﹤0.01% 931
2024
Q3 		$474K Buy
44,360
+31,185
+237% +$340K ﹤0.01% 695
2024
Q2 		$131K Buy
+13,175
New +$135K ﹤0.01% 946
2015
Q3 		– Sell
-65,500
Closed -$927K – 28
2015
Q2 		$927K Buy
+65,500
New +$787K 0.29% 28

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brevan Howard Capital Management's FOLD Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Amicus Therapeutics (FOLD) in Q4 2025, closing a stake of 31,235 shares — an estimated $246K sold.

Brevan Howard Capital Management first reported a position in FOLD in Q2 2015 and held it in 6 quarters. The position peaked at $927K in Q2 2015. 332 funds tracked by Wall St. Rank hold FOLD as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Amicus Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 31,235 Amicus Therapeutics shares in Q4 2025, an estimated $246K.
  • Brevan Howard Capital Management first reported a position in Amicus Therapeutics in Q2 2015 and held it in 6 quarters.
  • Brevan Howard Capital Management's Amicus Therapeutics position peaked at $927K in Q2 2015.
  • 332 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.